Anlon Healthcare Limited
24.35
INR
-1.28
(-4.99%)
ISIN
INE0Y8W01025
Return %
Stock
S&P 500
1Y
91.55
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Punitkumar R. Rasadia
- Full Time Employees
- 119
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Rajkot India
- Website
- anlon.in
- Similar Companies
- Business
- Anlon Healthcare Limited is a pharmaceutical and life sciences manufacturing company engaged in the research, development, production, and commercialization of active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and specialized healthcare solutions. Founded in 2013 and headquartered in Rajkot, Gujarat, India, the company operates across key business segments including Active Pharmaceutical Ingredients, Advanced Intermediates, Finished Pellets, and Contract Research and Manufacturing Services (CRAMS). The company's product and service portfolio includes: active pharmaceutical ingredients across diverse therapeutic areas such as cardiovascular, anti-diabetic, anti-fungal, central nervous system (CNS), anti-inflammatory, and gastrointestinal therapeutics; advanced organic intermediates and specialty fine chemicals for custom synthesis; ready-to-fill modified-release, enteric-coated, and sustained-release pellets; direct compression (DC) granules; custom chemical synthesis and route scouting; analytical method development and validation; and end-to-end contract development and manufacturing organization (CDMO) services for pharmaceutical formulators worldwide. Anlon Healthcare Limited serves generic drug manufacturers, proprietary pharmaceutical companies, and biotechnology firms across domestic and international markets, distributing its products across Asia, the Middle East, Africa, Europe, and Latin America. In recent developments, the company has expanded its manufacturing capacity through the commissioning of upgraded cGMP-compliant synthesis suites and expanded cleanroom facilities, broadened its product line with the introduction of new niche therapeutic intermediates and high-potency APIs, entered into long-term strategic supply and contract manufacturing agreements with multinational generic drug producers, and accelerated regulatory documentation filings to deepen penetration into regulated and semi-regulated export markets.